How Technology is Reshaping Aesthetic Medicine and Expanding Patient Options NEW YORK CITY, NY / ACCESS Newswire / April 1, 2025 / The field of cosmetic medicine is evolving at an unprecedented pace, ...

ORLANDO, FL / ACCESS Newswire / April 1, 2025 / MARIJUANA INC. (OTC PINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech company using exosomes in the treatment of cancer and other maladies, is ...

Investment/MiscellaneousM1 Kliniken AG: HAEMATO AG is reviewing an offer for the sale of its trading segment01-Apr-2025 / 17:13 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of ...

Four Industry Veterans Unite to Replace Single-Use Plastics with High-Performance Pulp Products DAYTON, OHIO / ACCESS Newswire / April 1, 2025 / PulpFixin, a groundbreaking company dedicated to ...

Flexible PBM implements an AI-powered platform to reduce specialty drug costs while improving patient care. MILWAUKEE, WISCONSIN / ACCESS Newswire / April 1, 2025 / Serve You Rx, a full-service ...

SALT LAKE CITY, UTAH / ACCESS Newswire / April 1, 2025 / CenExel, a leading clinical research site network, has launched a new mobile application designed to make it easier for patients to find and ...

Company stands out in Ethics, Environment, and Labor and Human Rights focus areas for 2024 pls logo Pace Life Sciences logo ...

Company has one year of cash to fund operationsCompany advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical ...

Congress, Johnson & Johnson MedTech presented pivotal 12-month safety and effectiveness data from the SmartfIRE study—offering new insights into the future of atrial fibrillation (AFib) treatment. The ...

EVERSANA, a global provider of commercial services to the life sciences industry, today announced it has been named an official Veeva AI Partner, managed by Veeva Systems, a global leader in cloud ...

MiscellaneousLonza Implements its Simplified and Streamlined Operating Model 01.04.2025 / 14:00 CET/CEST Lonza’s new simplified and streamlined operating model is designed to support its One Lonza ...

CDMO, has appointed Dr James Miskin as Non-Executive Director. James brings extensive experience in the cell and gene therapy sector, following a 23-year tenure at Oxford Biomedica. He oversaw ...